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Abstract
Systemic lupus erythematosus (SLE) is a predominantly female autoimmune disease that affects multiple organ systems.
Herein, we report on an X-chromosome gene association with SLE. Methyl-CpG-binding protein 2 (MECP2) is located on
chromosome Xq28 and encodes for a protein that plays a critical role in epigenetic transcriptional regulation of
methylation-sensitive genes. Utilizing a candidate gene association approach, we genotyped 21 SNPs within and around
MECP2 in SLE patients and controls. We identify and replicate association between SLE and the genomic element containing
MECP2 in two independent SLE cohorts from two ethnically divergent populations. These findings are potentially related to
the overexpression of methylation-sensitive genes in SLE.
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Introduction
Systemic lupus erythematosus (SLE) is a debilitating autoim-
mune disease that affects multiple organs and is associated with
significant morbidity and mortality. The disease predominantly
affects females with a female to male ratio ranging between 4.3–
13.6 to 1 [1]. The etiology of SLE remains incompletely
understood, although a number of genetic and environmental
factors have been implicated. Strong evidence supports an
important role for abnormal T cell DNA methylation in the
pathogenesis of SLE [2]. The expression of methylation sensitive
genes, such as ITGAL (CD11a), TNFSF7 (CD70), PRF1 (perforin)
and CD40LG (CD40L), is increased in T cells from SLE patients,
similar to normal T cells treated with DNA methylation inhibitors
such as 5-azacytidine [3,4,5,6]. Indeed, 5-azacytidine treated T
cells are autoreactive in vitro [7], and produce a SLE-like disease
upon adoptive transfer into mice [8]. In active SLE T cells, the
expression of DNA methyltransferase 1 (DNMT1), the main
enzyme that maintains DNA methylation during cell division, is
reduced [9], and the promoter sequences of the aforementioned
methylation-sensitive genes are hypomethylated [2,6]. DNA
methylation suppresses gene expression via several mechanisms
including the inability of transcription factors to bind methylated
promoter sequences [10]. Methyl-CpG-binding protein 2
(MECP2) plays a critical role in this process. MECP2 binds
methylcytosine residues and recruits histone deacetylase enzymes,
which by deacetylating histone residues, increase the charge
attraction between DNA and histone proteins and induce a
chromatin configuration that is inaccessible for the transcriptional
machinery [11]. Further, DNMT1 associates with and seems to
require MECP2 in order to maintain DNA methylation [12].
MECP2 is located on chromosome Xq28 in man and contains
four exons. It is ,76 kb in length and is characterized by the
presence of a very large intron 2 (,60 kb) and a highly conserved
39 UTR (,8.5 kb) [13]. The gene encodes a 486 amino acid
chromatin-associated protein that consists of three domains; a
methyl-binding domain, a transcription repression domain, and a
third domain on the C-terminal region that has not been fully
functionally characterized [13]. The facts that DNA methylation
sensitive genes are overexpressed in SLE [2], and that MECP2 is
critical in the transcriptional suppression of methylation sensitive
genes [11], make MECP2 an attractive candidate gene for SLE.
Using a candidate gene approach and a case-control genetic
association study, we report herein on the association of the
MECP2 gene region with SLE in two independent cohorts of SLE
patients and controls.
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We initially genotyped 628 Korean female SLE patients and 736
healthy female Korean controls across 21 single nucleotide
polymorphisms (SNPs) located within or around MECP2 (Table 1).
Nine SNPs had a minor allele frequency of more than 5% in our
Korean cohort and were used for further analysis. All 9 SNPs were
within expected Hardy-Weinberg proportions in both cases and
controls (Table2).Eightout ofthenine SNPs arewithintheMECP2
gene and showed significant association with SLE (Table 2 and
Fig. 1). The SNP having the strongest association in the Korean
SLE patients is rs17435 (Chi
2=22.83, OR=1.58, p=0.0000018)
followed by rs1734787 (Chi
2=21.58, OR=1.55, p=0.0000034),
rs1734792 (Chi
2=20.68, OR=1.53, p=0.0000054) and
rs1734791 (Chi
2=18.70, OR=1.51, p=0.000015). The SNPs
rs1734787, rs1734792, and rs1734791 are all in linkage disequilib-
rium with rs17435 (r
2=0.88, 0.92, and 0.86, respectively). We next
performed haplotype-based association test using Haploview 3.32
software [14] and WHAP [15]. Three haplotypes (with a frequency
of .1%) were identified (Table 3). The haplotype ‘‘ACTGCAAA’’
was identified as a disease risk haplotype with a frequency of 82.3%
in SLE patients compared to 75.3% in normal healthy controls
(OR=1.53, p=0.000013). On the other hand, the haplotype
‘‘GGAAATCG’’ is a protective haplotype with a frequency of
16.8% in SLE patients and 23.4% in normal healthy controls
(OR=0.66, p=0.000027) (Table 3). Frequencies of the homozy-
gous risk genotypes in the haplotype-forming SNPs were analyzed
and summarized in Table 4.
To replicate our initial results, we next genotyped 1080
European-derived independent SLE patients and 1080 healthy
unrelated controls matched for sex and race using the same 21
SNPs in the MECP2 region (Table 1). Fifteen SNPs had a minor
allele frequency of more than 5% in our European-derived SLE
patients and controls and were used for subsequent analysis. All
SNPs that were associated with SLE in Korean patients showed
significant association with the same risk alleles in the European-
derived cohort (Table 5 and Fig. 2). Similarly, the association with
these SNPs is confirmed when only analyzing females in the
European-derived SLE patients and controls, with the strongest
association observed in rs1734787, rs17435, rs1734791, and
rs1734792 (p values=0.0016, 0.0017, 0.0020, and 0.0022,
respectively). Our haplotype analysis in female European-derived
SLE patients and controls also identified 3 haplotypes with the
same risk and protective haplotypes as in the Korean cohort
(Table 6). Subset analysis of male European-derived SLE patients
and controls was not possible due to small sample size.
The impact of hidden population stratification on our
association study was assessed by genomic control (GC) by
estimating the inflation factor (l) in the samples. We estimated
l=1.06 in Korean and 1.08 in European-derived samples, hence
no significant population stratification was detected. These results
are also corroborated with our population structure estimates; one-
population model (homogeneous population) fit better than a two-
population model (admixture) for both cohorts.
Discussion
DNA methylation plays a critical role in tissue differentiation,
imprinting, transcriptional suppression of parasitic DNA, silencing
of transcriptional ‘‘noise’’, and X-chromosome inactivation [16].
Utilizing a candidate gene approach, we first identified significant
association with MECP2 SNPs and SLE in a cohort of Korean
SLE patients and controls. We next replicated the association with
MECP2 SNPs in an independent cohort of SLE patients and
controls of European descent. Indeed, the disease-associated alleles
in rs17435, rs1734787, rs1734792, and rs1734791 (T, C, A, and A





28 respectively (Table 7). Interestingly, the
disease associated alleles in these four MECP2 SNPs are ,4 times
more common in Korean as compared to European-derived
controls. This might suggest a possible explanation for the higher
frequency of SLE in people of Asian descent as compared to
Europeans.
MECP2 has been extensively studied in the setting of mental
retardation and, particularly, Rett syndrome, an X-linked
neurodevelopmental disease that has a cumulative incidence of
,1/10,000 females by the age of 12 years [17]. In the majority of
cases, this syndrome is caused by mutations in the MECP2 gene
[18]. MECP2-deficient mice demonstrate clinical neurological
findings similar to those observed in patients with Rett syndrome
[19,20], which can be reversed by MECP2 expression [21]. More
recently, mutations in the MECP2 gene have been recognized in a
number of other neuropsychiatric illnesses as well [22]. Identifying
MECP2 regulated genes had been a challenge in patients with
Rett syndrome [23]. Recent studies suggest that MECP2 binding
to DNA is selective and requires A/T sequences adjacent to
methylated CG sites [24]. In addition to its role in transcriptional
regulation, MECP2 interacts with the RNA-binding protein Y
box-binding protein 1 (YB-1) and plays a role in RNA splicing
[25].
Another interesting gene that is in close proximity to MECP2 is
IRAK1 (Interleukin-1 receptor-associated kinase1). Both MECP2
and IRAK1 are on the same haplotype block in combined Japanese
and Chinese individuals genotyped in the International HapMap
Project (www.hapmap.org). Moreover, this haplotype block
Table 1. SNPs genotyped in the MECP2 region in SLE patients
and controls
SNP Position (bp) Alleles Gene
rs2266890 152900916 A/G TMEM187
rs10127175 152937366 A/T IRAK1
rs2075596 152950586 A/G MECP2
rs3027933 152952068 C/G MECP2
rs3027935 152957662 A/G MECP2
rs3027939 152963772 T/C MECP2
rs17435 152965174 T/A MECP2
rs7050901 152967504 T/C MECP2
rs7059306 152968184 A/G MECP2
rs1624766 152970348 A/G MECP2
rs7884370 152976075 T/C MECP2
rs1734787 152978640 A/C MECP2
rs5987201 152983236 A/G MECP2
rs1734791 152984114 T/A MECP2
rs1734792 152994254 A/C MECP2
rs11156611 152997368 A/G MECP2
rs5987204 153000782 A/G MECP2
rs2239464 153001625 A/G MECP2
rs5986954 153002489 T/C MECP2
rs5945175 153011951 T/C LOC728653,MECP2
rs34371500 153850987 C/A -
doi:10.1371/journal.pone.0001727.t001
MECP2 Confer Risk of Lupus
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frequency of .0.05
SNP Risk allele Risk allele frequency* Chi2 OR (95% CI) p value
Permutation
p value HWE (p exact)
Cases n (%) Controls n (%) Cases Controls
rs2266890 A 804 (72.8) 848 (66.6) 10.94 1.35 (1.13–1.61) 0.0009 0.0029 1.00 0.24
rs2075596 A 1026 (81.7) 1103 (74.9) 18.05 1.49 (1.24–1.80) 0.000022 0.0001 0.59 0.56
rs3027933 C 1025 (81.6) 1103 (74.9) 17.61 1.48 (1.23–1.79) 0.000027 0.0001 0.35 0.56
rs17435 T 1036 (82.5) 1103 (74.9) 22.83 1.58 (1.31–1.90) 0.0000018 0.00001 0.33 0.85
rs1624766 G 1044 (83.1) 1128 (76.6) 17.59 1.50 (1.24–1.82) 0.000027 0.0001 0.15 0.31
rs1734787 C 1032 (82.2) 1101 (74.8) 21.58 1.55 (1.29–1.87) 0.0000034 0.00003 0.28 0.50
rs1734791 A 1032 (82.2) 1109 (75.3) 18.70 1.51 (1.25–1.82) 0.000015 0.00009 0.28 0.28
rs1734792 A 1018 (81.1) 1085 (73.7) 20.68 1.53 (1.27–1.83) 0.0000054 0.00003 0.52 0.78
rs2239464 A 1044 (83.1) 1127 (76.6) 17.94 1.51 (1.25–1.82) 0.000023 0.0001 0.09 0.30
OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.
*A total of 628 independent female SLE patients and 736 healthy unrelated female controls were genotyped
doi:10.1371/journal.pone.0001727.t002
Figure 1. Allelic association results and linkage disequilibrium (LD) plot of the chromosome Xq28 region around the MECP2 gene.
The allelic association p values of the SNPs analyzed are shown in the Korean cohort included in this study.
doi:10.1371/journal.pone.0001727.g001
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PLoS ONE | www.plosone.org 3 March 2008 | Volume 3 | Issue 3 | e1727Table 4. Frequencies of homozygous risk allele genotypes in Korean SLE patients compared to controls.
SNP Risk genotype Risk genotype frequency* Chi2 OR (95% CI) p value
Cases n (%) Controls n (%)
rs2075596 AA 421(67.0) 410 (55.7) 18.28 1.62 (1.30–2.02) 0.00002
rs3027933 CC 422 (67.2) 410 (55.7) 18.81 1.63 (1.31–2.03) 0.00001
rs17435 TT 431 (68.6) 412 (56.0) 22.98 1.72 (1.38–2.15) 0.0000016
rs1624766 GG 439 (69.9) 427 (58.0) 20.66 1.68 (1.34–2.11) 0.0000055
rs1734787 CC 428 (68.2) 408 (55.4) 23.10 1.72 (1.38–2.15) 0.0000015
rs1734791 AA 428 (68.2) 412 (56.0) 21.23 1.68 (1.35–2.10) 0.0000041
rs1734792 AA 415 (66.1) 398 (54.1) 20.29 1.66 (1.33–2.06) 0.0000067
rs2239464 AA 440 (70.1) 426 (57.9)) 21.70 1.70 (1.36–2.13) 0.0000032
OR, odds ratio; CI, confidence interval.
*A total of 628 independent female SLE patients and 736 healthy unrelated female controls were genotyped
doi:10.1371/journal.pone.0001727.t004
Table 5. Allele frequencies of MECP2 SNPs in European-derived SLE patients and controls
SNP Risk allele Risk allele frequency* Chi2 OR (95% CI) p value
Permutation
p value HWE (p value)
Cases n (%) Controls n (%) Cases Controls
rs2266890 A 418 (21.2) 354 (18.0) 6.24 1.22 (1.04–1.43) 0.013 0.068 0.45 0.21
rs2075596 A 371(18.5) 301(15.5) 8.59 1.28 (1.09–1.52) 0.0034 0.02 0.70 1
rs3027933 C 383 (19.1) 308 (15.3) 9.83 1.30 (1.10–1.53) 0.0017 0.01 0.72 0.92
rs3027935 G 1879 (93.8) 1865 (93.0) 1.01 1.14 (0.89–1.46) 0.31 0.79 0.03 0.14
rs3027939 G 104 (5.5) 97 (5.0) 0.57 1.12 (0.84–1.48) 0.45 0.92 0.02 0.68
rs17435 T 500 (24.9) 411 (20.5) 11.25 1.29 (1.11–1.49) 0.0008 0.0047 0.27 0.36
rs1624766 G 497 (24.8) 412 (20.5) 10.39 1.28 (1.10–1.48) 0.0013 0.0074 0.48 0.36
rs7884370 G 109 (5.4) 98 (4.9) 0.63 1.12 (0.85–1.48) 0.43 0.91 0.02 0.68
rs1734787 C 387 (19.3) 307 (15.3) 11.15 1.32 (1.12–1.56) 0.0008 0.0048 1 0.92
rs5987201 A 109 (5.4) 98 (4.9) 0.62 1.12 (0.85–1.48) 0.43 0.91 0.02 0.68
rs1734791 A 389 (19.4) 311 (15.5) 10.43 1.31 (1.11–1.54) 0.0012 0.0072 0.91 1
rs1734792 A 388 (19.3) 311 (15.5) 10.27 1.31 (1.11–1.54) 0.0014 0.0078 0.88 1
rs11156611 A 108 (5.4) 98 (4.9) 0.51 1.11 (0.84–1.47) 0.47 0.94 0.02 0.68
rs2239464 A 475 (23.7) 400 (19.9) 8.13 1.24 (1.07–1.45) 0.0044 0.026 0.72 0.27
rs5945175 G 115 (5.7) 103 (5.1) 0.70 1.12 (0.86–1.48) 0.40 0.89 0.85 0.45
OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.
*A total of 1080 independent cases and 1080 healthy unrelated controls matched for race and sex were genotyped
doi:10.1371/journal.pone.0001727.t005
Table 3. MECP2 haplotype frequencies in the Korean SLE patients and controls.
Frequency (%)
rs2075596 rs3027933 rs17435 rs1624766 rs1734787 rs1734791 rs1734792 rs2239464 Case Control OR (95% CI) p value
Haplotype1 A C T G C A A A 82.3 75.3 1.53 (1.26–1.85) 0.000013
Haplotype2 G G A A A T C G 16.8 23.4 0.66 (0.54–0.80) 0.000027
Haplotype3 G G T G A T C A 0.9 1.3 0.74 (0.36–1.50) 0.39
OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0001727.t003
MECP2 Confer Risk of Lupus
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in Toll-like receptor signaling and innate immune response [26]
makes this an important candidate gene for SLE.
We report on an X-chromosome association in SLE. A role for
an X-chromosome gene in this predominantly female disease has
long been anticipated. Male patients with Klinefelter’s syndrome
(47,XXY) have similar risk to develop SLE compared to females
(46,XX) (Scofield RH, et al Arthritis and Rheumatism 2003;
48:S383) . Possible explanations for the suggested gene-dose effect
are the presence of a SLE susceptibility gene(s) on the X-
chromosome, or the overexpression of an X-chromosome gene as
a result of loss of random X-chromosome inactivation, or both. X-
chromosome inactivation is largely mediated by DNA methylation
[27], and DNA methylation is defective in SLE T cells [2].
Hence, X-chromosome genes in SLE female patients and SLE
male patients with Klinefelter’s syndrome are available for
transcription from both copies on the two X-chromosomes. This
mechanism is suggested to explain the observed overexpression of
the X-chromosome gene CD40L in T cells from female SLE
patients [6]. Our findings provide evidence for SLE association
Figure 2. Allelic association results and linkage disequilibrium (LD) plot of the chromosome Xq28 region around the MECP2 gene.
The allelic association p values of the SNPs analyzed are shown in the European-derived cohort included in this study.
doi:10.1371/journal.pone.0001727.g002
Table 6. MECP2 haplotype frequencies in the European-derived female SLE patients and controls.
rs2075596 rs3027933 rs17435 rs1624766 rs1734787 rs1734791 rs1734792 rs2239464 Frequency (%) OR (95% CI) p value
Case Control
Haplotype1 A C T G C A A A 19.0 15.4 1.29 (1.08–1.53) 0.0044
Haplotype2 G G A A A T C G 77.0 81.0 0.81 (0.69–0.95) 0.012
Haplotype3 G G T G A T C A 4.0 4.2 0.96 (0.70–1.34) 0.82
OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0001727.t006
MECP2 Confer Risk of Lupus
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intimately involved in regulating the expression of methylation-
sensitive genes and in innate immune response.
In summary, the finding of strong association between the X-
chromosome region harboring MECP2 and SLE suggests an
important role for genetic and epigenetic interactions in the
pathogenesis of this disease. This might provide more insight for
the predominance of SLE in females and suggests a novel
mechanism to explain the observed overexpression of methylation-
sensitive genes in SLE T cells and the resulting T cell
autoreactivity in SLE patients.
Materials and Methods
SLE patients and controls
Korean SLE patients and controls were recruited at the
Hospital for Rheumatic Diseases, Hanyang University, Seoul,
Korea. All patients were of Korean descent and met the 1997
American College of Rheumatology SLE classification criteria. A
total of 628 independent female SLE patients and 736 healthy
unrelated female controls were studied. No two SLE patients or two
controls are blood relatives to avoid intrafamilial correlation bias.
Another independent cohort of SLE patients of European
descent was studied. This cohort consisted of 1080 independent
cases and 1080 healthy unrelated controls matched for race and
sex and recruited in the SLE genetics studies at the Oklahoma
Medical Research Foundation as well as from collaborators in the
United States, United Kingdom, and Sweden. This cohort
included 928 females and 152 males in each of the case and
control groups. All SLE patients met the 1997 American College
of Rheumatology SLE classification criteria.
The study was approved by the Institutional Review Boards of
Hanyang University Medical Center, University of Oklahoma
Health Sciences Center, and the Oklahoma Medical Research
Foundation. Participants in the study gave written informed
consent for the genotyping.
Genotyping
Twenty one SNPs within or around the MECP2 gene (Table 1)
were genotyped on an Illumina BeadStation 500GX instrument
using Illumina Infinum II genotyping assays following manufac-
turer’s recommendations. The SNPs were selected to cover the
entire length of MECP2 and the immediate genetic regions in both
the 59 and 39 ends of MECP2. SNPs were selected from the
published SNP databases (http://www.ncbi.nlm.nih.gov/pro-
jects/SNP/). In general, we selected SNPs that have been
validated by at least two groups, that have a minor allele
frequency of $5%, and that had been tested successfully on the
Illumina genotyping platform that we used in our study.
Genotyping data were only used from samples with a call rate
greater than 90% of the SNPs screened (98.05% of the samples).
The average call rate for all samples was 97.18%.
Data analysis
A population-based case-control statistical design was employed.
ForeachtestedSNP, the qualityof the genotypingdata was assessed
by predetermined quality control inclusion criteria (MAF.5%,
SNP call rate.90%, and HWE p value.0.01 among the controls).
A Pearson’s Chi square was calculated for the frequency of allele
associations in cases and controls. P values of ,0.05 were
considered statistically significant. Odds ratios were calculated
under the assumption of normality. Fisher’s exact test was used to
test for deviation from Hardy-Weinberg equilibrium in the
genotyped SNPs in the cases and controls. Permutation p values
were calculated to correct for multiple testing using Haploview 3.32
[14]. Haplotype frequencies were estimated using the expectation–
maximization algorithm implemented in Haploview 3.32 [14] and
WHAP [15]. Haplotype-based association analysis was used to
perform regression-based omnibus haplotype frequency tests and
haplotype-specific tests, implemented in WHAP. We also used pair-
wise SNP correlation (r
2) structure between the two populations to
identifytheminimumhaplotypelength whichcould carry the riskof
SLE development. To control for possible confounding due to
population stratification, we used genomic control (GC) as well as
structured association analysis. A panel of 63 randomly chosen
‘‘null’’ SNPs genotyped on the same Illumina SNP platform was
used for GC and for estimating hidden population structure.
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